We are live on ! Find out more

Envoy Medical

COCH

Market cap $46.1M

0.5955 USD

-0.0004

0.07%

At close Updated Oct 23, 4:00 PM EDT

Pre-market

After hours

0.5720

-0.0235

3.95%

1 day

-0.07%

5 days

-8.38%

1 month

-17.52%

3 months

-9.91%

6 months

-13.7%

Year to date

-14.4%

1 year

-27.6%

5 years

-93.89%

10 years

-93.9%

About: Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.

Employees: 47

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 85.7%

Negative 14.3%

Envoy Medical Announces Reverse Stock Split

White Bear Lake, Minnesota--(Newsfile Corp. - October 22, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced that it will implement a 1-for-10 reverse stock split of its outstanding shares of Class A common stock ("Common Stock"), effective at 12:01 a.m. Eastern Time on October 26, 2026 (the "Reverse Split").

Envoy Medical Announces Reverse Stock Split

Envoy Medical Hits Six-Month Milestone, Marks Halfway Point in Final Stage of Data Collection, and Highlights Differentiated Device Design

Company Believes It Is the First to Reach This Milestone in a U.S. Pivotal Trial of a Fully Implanted Cochlear Implant Remains on Track to Reach 12-Month Visit Milestone by Early Q2 2027 and Submit Final Clinical PMA Module by End of Q2 2027 White Bear Lake, Minnesota--(Newsfile Corp. - October 20, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced that it has surpassed the six-month follow-up visit milestone for the Company's pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant. This milestone signifies the halfway point in the trial's final stage of data collection as each participant is followed for a total of 12 months.

Envoy Medical Hits Six-Month Milestone, Marks Halfway Point in Final Stage of Data Collection, and Highlights Differentiated Device Design

Envoy Medical Submits Second Module of Modular Premarket Approval Application to FDA for Breakthrough Designated Acclaim(R) Cochlear Implant

Second of Four Planned Modules Moves Rolling FDA Review Forward Advances Toward Targeted Completion of the Final Clinical Module Submission in Q2 2027 White Bear Lake, Minnesota--(Newsfile Corp. - October 12, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced the submission of the second module of its Modular Premarket Approval ("PMA") application to the U.S. Food and Drug Administration ("FDA") for the Acclaim® cochlear implant, which has received FDA Breakthrough Device Designation. The second module, which included primarily engineering information, follows the Company's submission of the first module on June 30, 2026.

Envoy Medical Submits Second Module of Modular Premarket Approval Application to FDA for Breakthrough Designated Acclaim(R) Cochlear Implant

Envoy Medical Announces New Patents, Further Expanding Global Patent Portfolio

Canadian and Hong Kong Patents Continue to Strengthen Intellectual Property Protection Across Envoy Medical's Fully Implanted Hearing Platform White Bear Lake, Minnesota--(Newsfile Corp. - September 22, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the grant of two additional international patents, expanding its global intellectual property portfolio to 97 patents, consisting of 40 U.S. and 57 foreign patents. In addition, the Company has 26 pending foreign applications and 9 pending U.S. applications.

Envoy Medical Announces New Patents, Further Expanding Global Patent Portfolio

Envoy Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14th-16th

White Bear Lake, Minnesota--(Newsfile Corp. - September 2, 2026) - Envoy Medical ® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced that Brent Lucas, Envoy Medical's Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference, on September 14-16, 2026 at the Lotte New York Palace Hotel in New York City.

Envoy Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14th-16th

Zacks Investment Research

Envoy Medical, Inc. (COCH) Reports Q2 Loss, Misses Revenue Estimates

Envoy Medical, Inc. (COCH) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.32 per share a year ago.

Envoy Medical, Inc. (COCH) Reports Q2 Loss, Misses Revenue Estimates

Envoy Medical Reports Second Quarter 2026 Results and Achieves Key Regulatory and Clinical Milestones

Submitted First Module of Modular PMA Application to FDA Subsequent to Quarter End, the Company Reported Positive 12-Month Stage 1 Data Showing Continued Improvement in Speech Perception White Bear Lake, Minnesota--(Newsfile Corp. - August 10, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today reported financial results for the second quarter ended June 30, 2026, and provided a business update, highlighting continued execution on its corporate initiatives. "The second quarter moved us measurably closer to bringing our fully implanted cochlear implant to market," said Brent Lucas, Chief Executive Officer of Envoy Medical.

Envoy Medical Reports Second Quarter 2026 Results and Achieves Key Regulatory and Clinical Milestones

Zacks Investment Research

Envoy Medical, Inc. (COCH) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Envoy Medical, Inc. (COCH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Envoy Medical, Inc. (COCH) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Envoy Medical Surpasses Three-Month Visit Milestone for All 56 Patients in Pivotal Clinical Trial

White Bear Lake, Minnesota--(Newsfile Corp. - July 21, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has surpassed the three-month milestone for all 56 patients enrolled in the Company's pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant. This marks another important clinical trial milestone as the Company continues to build momentum with the hearing industry.

Envoy Medical Surpasses Three-Month Visit Milestone for All 56 Patients in Pivotal Clinical Trial

Envoy Medical Reports Positive 12-Month Data Showing Continued Improvement in Speech Perception in Study of First-of-Its-Kind Fully Implanted Cochlear Implant

Mean CNC word recognition scores for Stage 1 cohort improved to 53.2% at 12 months from 15.2% pre-implantation, a 38.0 percentage point gain that continued to build on the 24.0 percentage point improvement reported at 6 months White Bear Lake, Minnesota--(Newsfile Corp. - July 14, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced positive 12-month data from the first 10 participants in Stage 1 of its pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant. The Stage 1 cohort demonstrated a mean Consonant-Nucleus-Consonant ("CNC") word recognition score of 53.2% at their 12-month visits, up from a mean pre-implantation baseline of 15.2% — a 38.0 percentage point improvement.

Envoy Medical Reports Positive 12-Month Data Showing Continued Improvement in Speech Perception in Study of First-of-Its-Kind Fully Implanted Cochlear Implant

See News Rankings

Price charts implemented using Lightweight Charts™